78 results
Page 2 of 4
8-K
EX-10.1
jlebu08uifndw dv0io
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.2
gez0ck6c
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
bn6f47fxf10j0i
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
g3njv4h2o rstta73z3a
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-99.2
kjy5g16c 4o0lrmeg
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.2
py2h w3qx
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
w65xyca1z9ub7xam
13 Jan 20
Other Events
8:06am
8-K
EX-99.1
0kq0ofj
2 Dec 19
Other Events
5:18pm
424B5
f122kul10sb09ufzi0z
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
6wvdfqn
26 Nov 19
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.2
ln4 jip28g1upfo
20 Nov 19
Other Events
7:05am